A. Towse

发表

Economic incentives for evidence generation: promoting an efficient path to personalized medicine.

L. Garrison, A. Towse, 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare

B. Jönsson, J. Michaels, A. Towse, 2018, The European Journal of Health Economics.

Should NICE’s threshold range for cost per QALY be raised? Yes

A. Towse, 2009, BMJ : British Medical Journal.

The Future of Global Health Procurement: Issues around Pricing Transparency

Jimena, L. Garrison, K. Chalkidou, 2019 .

Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries.

P. Danzon, A. Mulcahy, A. Towse, 2011, Health affairs.

Cost-effectiveness Thresholds: Economic and Ethical Issues

N. Devlin, A. Towse, C. Pritchard, 2002 .

European Union Pharmaceutical Markets: A Case for Differential Pricing?

Adrian Towse, Zeba M. Khan, L. Garrison, 2015 .

Value of Drugs in Practice

A. Towse, 2014 .

How can HTA meet the needs of health system and government decision makers

C. Henshall, A. Towse, G. Hampson, 2017 .

Gene therapy: evidence, value and affordability in the US health care system.

C. Henshall, S. Pearson, A. Towse, 2018, Journal of comparative effectiveness research.

Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value

C. Henshall, S. Pearson, G. Marsden, 2017 .

ASSESSING VALUE, BUDGET IMPACT, AND AFFORDABILITY IN ASIA

C. Henshall, A. Towse, G. Hampson, 2017, International Journal of Technology Assessment in Health Care.

Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies

C. Henshall, A. Towse, G. Hampson, 2017 .

A Critique of the Paper "The Estimated Costs of Production and Potential Prices for the World Health Organization Essential Medicines List"

K. Hernandez-Villafuerte, A. Towse, B. Shaw, 2018 .

Incentives for New Drugs to Tackle Anti-Microbial Resistance

A. Towse, J. Mestre-Ferrandiz, J. Ferraro, 2017 .

International Decision Support Initiative: Mapping of Priority-Setting in Health for 17 Low and Middle Countries Across Asia, Latin America and Africa

K. Chalkidou, K. Hernandez-Villafuerte, A. Towse, 2015 .

Measuring value: pharmacoeconomics theory and practice

M. Drummond, C. Sorenson, A. Towse, 2012 .

Uncertainty and Cures: Discontinuation, Irreversibility, and Outcomes-Based Payments: What Is Different About a One-Off Treatment?

E. Fenwick, A. Towse, 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Not cost-effective at zero price: valuing and paying for combination therapies in cancer

N. Latimer, C. Henshall, A. Towse, 2021, Expert review of pharmacoeconomics & outcomes research.

Affordability of New Technologies: The Next Frontier.

J. Mauskopf, A. Towse, 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?

L. Garrison, A. Towse, R. Puig-Peiró, 2012 .

The drug budget silo mentality in Europe: an overview.

L. Garrison, A. Towse, 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria

A. Towse, H. Kettler, M. Berdud, 2016 .

Promoting cost-effective prescribing

A. Towse, N. Wells, 1995, BMJ.

Results From an Early Economic Evaluation of the Use of a Novel Point of Care Device for Diagnosis of Suspected Acute Coronary Syndrome Patient Within the Emergency Department in the National Health Service in England.

A. Stainthorpe, A. Towse, M. Bajre, 2021, Cardiology and Cardiovascular Medicine.

How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine?

Rachel Silverman, K. Chalkidou, A. Towse, 2021, Value in Health.

The UK Pharmaceutical Market

A. Towse, 2012, PharmacoEconomics.

The Societal Value of Vaccines: Expert-Based Conceptual Framework and Methods Using COVID-19 Vaccines as a Case Study

M. Drummond, M. Drummond, L. Steuten, 2022, medRxiv.

Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions

Steven D. Pearson, B. Dreitlein, A. Towse, 2018 .

Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations.

L. Garrison, M. Recht, E. Sawyer, 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents

Adrian Towse, P. Danzon, A. Towse, 2003, International Journal of Health Care Finance and Economics.

Drugs and Vaccines for Developing Countries

A. Towse, D. Ridley, H. Kettler, 2012 .

Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?

Adrian Towse, A. Towse, 2010, British journal of clinical pharmacology.

Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics

L. Garrison, A. Towse, 2017, Journal of personalized medicine.

Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report.

Sharon-Lise Normand, Adrian Towse, Art Sedrakyan, 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi‐stakeholder, international workshop

L. Sansom, R. Ward, N. Latimer, 2021, BMC Health Services Research.

Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation.

J. Rex, A. Towse, J. Mestre-Ferrandiz, 2017, Health policy.

Medical negligence and the NHS: an economic analysis.

A Towse, P. Danzon, A. Towse, 1999, Health economics.

GUIDELINES FOR THE ECONOMIC EVALUATION OF PHARMACEUTICALS : Can the UK learn from Australia and Canada ? QhE

A. Towse, 2012 .

Learning from Thailand's health reforms

Anne Mills, Adrian Towse, A. Mills, 2004, BMJ : British Medical Journal.

Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.

Katherine Payne, David Veenstra, Uwe Siebert, 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

If it ain't broke, don't price fix it: the OFT and the PPRS.

A. Towse, 2007, Health economics.

Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context

Adrian Towse, P. Danzon, A. Towse, 2012, Health economics.

Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.

Andrew Briggs, Louis P Garrison, Adrian Towse, 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Can’t Get No Satisfaction? Will Pay for Performance Help?

Adrian Towse, L. Garrison, A. Towse, 2012, PharmacoEconomics.

Health Economic Perspectives of Genomics

Sarah Wordsworth, James Buchanan, Adrian Towse, 2015 .

Learning from Thailands health reforms.

A. Mills, A. Towse, Tangcharoensathien, 2004 .

The Evolution of HTA in Emerging Markets Health Care Systems: Analysis to Support a Policy Response

L. P. Garrison, Adrian Towse, E. Hawe, 2011 .

Incentives for R&D for New Antimicrobial Drugs

A. Towse, Priya Sharma, 2011 .

New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options

A. Towse, Priya Sharma, 2010 .

Approaches to Aggregation and Decision Making—A Health Economics Approach: An ISPOR Special Task Force Report [5]☆

Anirban Basu, Patricia M Danzon, Michael F Drummond, 2018, Value in Health.

Mapping Priority Setting in Health in 17 Countries Across Asia, Latin America, and sub-Saharan Africa

K. Chalkidou, K. Hernandez-Villafuerte, A. Towse, 2016, Health systems and reform.

Real-world evidence for coverage decisions: opportunities and challenges.

Adrian Towse, Chris Henshall, Grace Hampson, 2018, Journal of comparative effectiveness research.

The economics of gene therapy and of pharmacogenetics.

P. Danzon, A. Towse, 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty

A. Towse, H. Kettler, H. Kettler, 2002 .

Genetic screening, health care and the insurance industry

A. Towse, D. Ossa, 2004, The European Journal of Health Economics, formerly: HEPAC.

The efficient use of pharmaceuticals: does Europe have any lessons for a Medicare drug benefit?

A. Towse, 2003, Health affairs.

Additional Elements of Value for Health Technology Assessment Decisions

A. Fischer, C. Henshall, A. Towse, 2017 .

Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?

P. Danzon, A. Towse, M. Garau, 2011 .

The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries

B. Zamora, A. Towse, A. Cole, 2018 .

Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals

P. Lorgelly, R. Sullivan, A. Towse, 2018 .

Indication-specific pricing of pharmaceuticals in the US healthcare system.

C. Henshall, S. Pearson, A. Towse, 2017, Journal of comparative effectiveness research.

An Ambitious USG Advanced Commitment for Subscription-Based Purchasing of Novel Antimicrobials and Its Expected Return on Investment

A. Towse, 2022 .

Working towards a sustainable, healthy market for vaccines: A framework to support evidence-based policymaking

A. Towse, L. Steuten, Isha Sharma, 2022, Vaccine.

Cornerstones of "Fair" Drug Coverage: Appropriate Cost - Sharing and Utilization Management Policies for Pharmaceuticals

C. Henshall, S. Pearson, A. Towse, 2020 .

Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis.

Louis P Garrison, Adrian Towse, L. Garrison, 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis.

Louis P Garrison, Adrian Towse, L. Garrison, 2007, Health affairs.

Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].

Patricia M Danzon, Michael F Drummond, Mark V Pauly, 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Understanding the Economic Value of Molecular Diagnostic Tests: Case Studies and Lessons Learned

L. Garrison, D. Veenstra, J. Carlson, 2013, Journal of personalized medicine.

Advance price or purchase commitments to create markets for treatments for diseases of poverty: lessons from three policies.

A. Towse, H. Kettler, 2005, Bulletin of the World Health Organization.

BRIEFING NOTE ON ADVANCE PURCHASE COMMITMENTS

A. Towse, M. Kremer, H. Williams, 2005 .

Transferability of HTA

C. Henshall, A. Towse, G. Hampson, 2017 .

Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases

M. Jofre-Bonet, A. Towse, M. Berdud, 2022, Applied Economics Letters.

A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].

Milton C Weinstein, Scott D Ramsey, Louis P Garrison, 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Comparative and Relative Effectiveness: A Challenge for Health Systems, Regulators, or Pharmaceutical Companies?

A. Towse, 2014 .

UNDERSTANDING VARIATIONS IN RELATIVE EFFECTIVENESS: A HEALTH PRODUCTION APPROACH

Clare McGrath, Bengt Jonsson, Adrian Towse, 2015, International Journal of Technology Assessment in Health Care.

Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation

A. Towse, A. Cole, 2018 .

A Strategy to Support Efficient Development and Use of Innovations in Personalized Medicine and Precision Medicine.

L. Garrison, A. Towse, 2019, Journal of managed care & specialty pharmacy.

Policy perspectives on alternative models for pharmaceutical rebates: a report from the Institute for Clinical and Economic Review Policy Summit.

C. Henshall, S. Pearson, A. Towse, 2019, Journal of comparative effectiveness research.

National Institute for Clinical Excellence (NICE): Is Economic Appraisal Working?

A. Towse, C. Pritchard, 2012, PharmacoEconomics.

A framework to guide the optimal development and use of real-world evidence for drug coverage and formulary decisions.

Adrian Towse, Chris Henshall, Grace Hampson, 2018, Journal of comparative effectiveness research.

The Genomic Revolution: Is the Real Risk Under-Investment Rather than Bankrupt Health Care Systems?

P. Danzon, A. Towse, 2000, Journal of health services research & policy.

Impact of pharmacogenetics on health care and health economics

P. Sagnier, T. Weihrauch, G. Glaeske, 2001, International Journal of Pharmaceutical Medicine.

The Pricing and Reimbursement of Pharmaceuticals

A. Towse, 2012, PharmacoEconomics (Auckland).

Value of the Pharmaceutical Industry to the UK Economy

A. Towse, D. Hale, 1995 .

International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework.

Karl Claxton, Milton C Weinstein, Maarten J. IJzerman, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paying for Cures: Perspectives on Solutions to the "Affordability Issue".

D. Messner, E. Tambor, A. Towse, 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Real-world evidence for coverage decisions: opportunities and challenges.

C. Henshall, S. Pearson, A. Towse, 2018, Journal of comparative effectiveness research.

Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare

B. Jönsson, J. Michaels, A. Towse, 2018, The European Journal of Health Economics.

Policymakers in both Europe and the United States need to emphasize ways to make health care delivery more efficient, rather than singling out drug spending for special attention.

A. Towse, 2003 .

A theory on ICER pricing and optimal levels of cost-effectiveness thresholds: a bargaining approach

A. Towse, M. Berdud, J. Ferraro, 2023, Frontiers in health services.

International Public Goods and Transfer of Technology under a Globalized Intellectual Property Regime: Theory and Implementation of Differential Pricing for Pharmaceuticals

P. Danzon, A. Towse, 2005 .